基于共价靶向策略与药代动力学的FAP靶向放射性药物初步研究
本研究开发了两种新型FAP靶向放射性药物[68Ga]Ga-DOTA-mFS-FAP-2286和[68Ga]Ga-DOTA-mFS-KERERG-FAP-2286,旨在解决[68Ga]Ga-DOTA-mFS-FAPI-04在唾液腺、甲状腺和胰腺高摄取的问题。结果显示两者均具有良好靶向特异性,其中[68Ga]Ga-DOTA-mFS-KERERG-FAP-2286仅经泌尿系统排泄,在原发肿瘤、淋巴结转移和远处转移中SUVmax均显著高于[68Ga]Ga-DOTA-FAP-2286(均p<0.05)。
要点
- 两种新型FAP靶向药物克服了[68Ga]Ga-DOTA-mFS-FAPI-04在唾液腺、甲状腺和胰腺高摄取的缺陷。
- [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286仅经泌尿系统排泄,药代动力学性质更优。
- [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286在肿瘤病灶中SUVmax显著高于[68Ga]Ga-DOTA-FAP-2286。
核心结论
- 两种新型FAP靶向放射性药物均有效克服了[68Ga]Ga-DOTA-mFS-FAPI-04在唾液腺、甲状腺和胰腺高摄取的缺点。
- [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286具有仅经泌尿系统排泄的优越药代动力学特征,且诊断效能可能优于[68Ga]Ga-DOTA-FAP-2286。
研究设计与样本
- 本研究为初步研究,开发了[68Ga]Ga-DOTA-mFS-FAP-2286和[68Ga]Ga-DOTA-mFS-KERERG-FAP-2286两种新型放射性药物并进行评估。
主要发现
- [68Ga]Ga-DOTA-mFS-FAP-2286表现出肝胆和泌尿双排泄途径,而[68Ga]Ga-DOTA-mFS-KERERG-FAP-2286仅经泌尿系统排泄。
- [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286在原发肿瘤中的SUVmax为11.03 ± 1.45,显著高于[68Ga]Ga-DOTA-FAP-2286的5.47 ± 1.66(p < 0.05)。
- [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286在淋巴结转移中的SUVmax为12.13 ± 2.22,显著高于[68Ga]Ga-DOTA-FAP-2286的5.70 ± 1.08(p < 0.05)。
- [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286在远处转移中的SUVmax为12.03 ± 6.56,显著高于[68Ga]Ga-DOTA-FAP-2286的6.83 ± 0.36(p < 0.05)。
临床怎么用
- [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286因仅经泌尿系统排泄且肿瘤摄取显著更高,可能成为FAP靶向PET显像的候选药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In tumor imaging and therapy, fibroblast activation protein (FAP)-targeted radiotracers remains a research hotspot. The recently reported [68Ga]Ga/[177Lu]Lu-DOTA-mFS-FAPI-04 has been demonstrated to address limitations in conventional FAP-targeted agents, such as low tumor uptake, short retention time, and suboptimal therapeutic efficacy. However, [68Ga]Ga-DOTA-mFS-FAPI-04 positron emission tomography (PET) clinical imaging revealed high uptake in salivary glands, thyroid, and pancreas, necessitating further structural optimization. To address this limitation, we developed two novel radiopharmaceuticals. RESULTS: [68Ga]Ga-DOTA-mFS-FAP-2286 and [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286 demonstrated favorable targeting specificity and diagnostic efficacy. [68Ga]Ga-DOTA-mFS-FAP-2286 exhibited dual excretion pathways (hepatobiliary and urinary systems), whereas [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286 showed exclusive urinary excretion, demonstrating superior pharmacokinetic properties. [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286 exhibited significantly enhanced tracer uptake compared to [68Ga]Ga-DOTA-FAP-2286 in primary tumors (SUVmax: 11.03 ± 1.45 vs. 5.47 ± 1.66), lymph node metastases (SUVmax: 12.13 ± 2.22 vs. 5.70 ± 1.08), and distant metastases (SUVmax: 12.03 ± 6.56 vs. 6.83 ± 0.36) (all p < 0.05). CONCLUSION: Both [68Ga]Ga-DOTA-mFS-FAP-2286 and [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286 effectively overcame the drawback of high uptake in salivary glands, thyroid, and pancreas observed with [68Ga]Ga-DOTA-mFS-FAPI-04. [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286 demonstrated superior pharmacokinetic characteristics with urinary excretion and showed the potential for superior diagnostic efficacy compared with [68Ga]Ga-DOTA-FAP-2286.
引用
- Ai Y, Jin Z, Wu T, et al. Preliminary study of FAP-targeted radiopharmaceuticals based on covalent targeting strategy and pharmacokinetic characteristics. EJNMMI Res. 2026. PMID: 41979762. doi:10.1186/s13550-026-01431-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。